Lv5
1257 积分 2021-07-21 加入
Pharmacotherapy for metabolic dysfunction-associated steatohepatitis: heart–liver co-management
1天前
已完结
Liver stiffness dynamics in European populations (LiverScreen): a longitudinal, multicentre, prospective, population-based cohort study
12天前
已完结
Prevalence and associated factors of metabolic dysfunction-associated steatotic liver disease in Taiwan, 2001–2021
21天前
已完结
Community-based lifestyle modification programme for non-alcoholic fatty liver disease: a randomized controlled trial
22天前
已完结
Community-based lifestyle modification programme for non-alcoholic fatty liver disease: A randomized controlled trial
24天前
已完结
The central role of primary care in liver health
24天前
已完结
The role of primary care in response to the global liver disease syndemic: a Lancet Gastroenterology & Hepatology Commission
24天前
已完结
Identifying MASLD patient eligibility for pharmacological therapy: the need to integrate evidence into clinical practice
25天前
已完结
The use of pharmacotherapies in non-cirrhotic metabolic dysfunction-associated steatohepatitis: a UK expert consensus
1个月前
已完结
Pharmaco‐Economic Assessment of Screening Strategies for High‐Risk MASLD in Primary Care
1个月前
已完结
皖公网安备34019202002308
